Abstract
The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Current Drug Therapy
Title:Complications of Anti-Vascular Endothelial Growth Factor Drugs
Volume: 7 Issue: 2
Author(s): Michael Tolentino
Affiliation:
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Abstract: The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Export Options
About this article
Cite this article as:
Tolentino Michael, Complications of Anti-Vascular Endothelial Growth Factor Drugs, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800675959
DOI https://dx.doi.org/10.2174/157488512800675959 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 4
Current Topics in Medicinal Chemistry Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Intravitreal Triamcinolone in Diabetic Retinopathy
Current Diabetes Reviews Ascorbic Acid and Gene Expression: Another Example of Regulation of Gene Expression by Small Molecules?
Current Genomics Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes
Current Protein & Peptide Science Evaluation of Homocysteine, Vitamin B12 and Folic Acid Levels During all the Trimesters in Pregnant and Preeclamptic Womens
Current Hypertension Reviews Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Diabetes and Gestational Hypertension
Current Hypertension Reviews How to Measure Exercise Performance
Current Respiratory Medicine Reviews Analysis of Captopril in Human Plasma Using Gas Chromatography-Mass Spectrometry (GCMS) with Solid-Phase Extraction (SPE)
Current Analytical Chemistry Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews